A prospective protocol for nasopharyngeal carcinoma in children and adolescents

Nasopharyngeal carcinoma (NPC) is very rare in childhood. It differs from its adult counterpart in the prevalence of the nonkeratinizing, undifferentiated subtype and by an advanced clinical stage at onset and better chances of survival. The risk of long‐term treatment‐related toxicity also may be a more important issue in younger individuals.

[1]  Chong Zhao,et al.  Intensity‐modulated radiation therapy reduces radiation‐induced trismus in patients with nasopharyngeal carcinoma , 2011, Cancer.

[2]  Chong Zhao,et al.  Local control, survival, and late toxicities of locally advanced nasopharyngeal carcinoma treated by simultaneous modulated accelerated radiotherapy combined with cisplatin concurrent chemotherapy , 2011, Cancer.

[3]  Y. Young,et al.  Comparison of otologic complications between intensity-modulated and two-dimensional radiotherapies in nasopharyngeal carcinoma patients , 2010, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[4]  A. Ferrari,et al.  Peculiar features and tailored management of adult cancers occurring in pediatric age , 2010, Expert review of anticancer therapy.

[5]  A. Ferrari,et al.  Differential features of nasopharyngeal carcinoma in children and adults: A SEER study , 2010, Pediatric blood & cancer.

[6]  M. Frikha,et al.  [Pediatric nasopharyngeal carcinoma: Anatomoclinic aspects, therapeutic results and evolutive particularities]. , 2010, Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique.

[7]  S. Nill,et al.  Intensity modulated radiotherapy (IMRT) in the treatment of children and Adolescents - a single institution's experience and a review of the literature , 2009, Radiation oncology.

[8]  Giovanni Cecchetto,et al.  Evaluating access to pediatric cancer care centers of children and adolescents with rare tumors in Italy: The TREP project , 2009, Pediatric blood & cancer.

[9]  C. Choi,et al.  Sensorineural hearing loss after treatment of nasopharyngeal carcinoma: a longitudinal analysis. , 2009, International journal of radiation oncology, biology, physics.

[10]  A. Varan,et al.  Pediatric and young adult nasopharyngeal carcinoma patients treated with preradiation Cisplatin and docetaxel chemotherapy. , 2009, International journal of radiation oncology, biology, physics.

[11]  Chun-Ta Liao,et al.  Staging of untreated nasopharyngeal carcinoma with PET/CT: comparison with conventional imaging work-up , 2009, European Journal of Nuclear Medicine and Molecular Imaging.

[12]  R. Abouqal,et al.  Nasopharyngeal carcinoma in adolescents: a retrospective review of 42 patients , 2009, European Archives of Oto-Rhino-Laryngology.

[13]  S. Pai,et al.  Nasopharyngeal carcinoma in children: comparison of conventional and intensity-modulated radiotherapy. , 2008, International journal of radiation oncology, biology, physics.

[14]  F. Bray,et al.  Age-Incidence Curves of Nasopharyngeal Carcinoma Worldwide: Bimodality in Low-Risk Populations and Aetiologic Implications , 2008, Cancer Epidemiology Biomarkers & Prevention.

[15]  S.H. Huang,et al.  The incidence and risk of second primary cancers in patients with nasopharyngeal carcinoma: a population-based study in Taiwan over a 25-year period (1979-2003). , 2008, Annals of Oncology.

[16]  J. Klijanienko,et al.  Radiation and chemotherapy combination for nasopharyngeal carcinoma in children: Radiotherapy dose adaptation after chemotherapy response to minimize late effects , 2008, Pediatric blood & cancer.

[17]  H. Heslop,et al.  A Single Institution Experience With Pediatric Nasopharyngeal Carcinoma: High Incidence of Toxicity Associated With Platinum-based Chemotherapy Plus IMRT , 2007, Journal of pediatric hematology/oncology.

[18]  A. Ferrari,et al.  The challenge of very rare tumours in childhood: the Italian TREP project. , 2007, European journal of cancer.

[19]  Yi Yu,et al.  Sustained elevation of Epstein–Barr virus antibody levels preceding clinical onset of nasopharyngeal carcinoma , 2007, British Journal of Cancer.

[20]  U. Abacıoğlu,et al.  Treatment results of 165 pediatric patients with non-metastatic nasopharyngeal carcinoma: a Rare Cancer Network study. , 2006, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[21]  A. Varan,et al.  Treatment results of 84 patients with nasopharyngeal carcinoma in childhood , 2006, Pediatric blood & cancer.

[22]  C. Hess,et al.  Treatment of nasopharyngeal carcinoma in children and adolescents , 2005, Cancer.

[23]  Adrian P Gee,et al.  Treatment of nasopharyngeal carcinoma with Epstein-Barr virus--specific T lymphocytes. , 2005, Blood.

[24]  G. Swanson,et al.  Preradiation chemotherapy with methotrexate, cisplatin, 5‐fluorouracil, and leucovorin for pediatric nasopharyngeal carcinoma , 2005, Cancer.

[25]  J. Berkhof,et al.  The additional value of chemotherapy to radiotherapy in locally advanced nasopharyngeal carcinoma: a meta-analysis of the published literature. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  Yau-Huei Wei,et al.  Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma. , 2004, The New England journal of medicine.

[27]  P. Navarria,et al.  Undifferentiated nasopharyngeal carcinoma in children and adolescents: comparison between staging systems. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[28]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[29]  M. Leblanc,et al.  Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  Kathryn Flynn,et al.  Clonal proliferations of cells infected with Epstein-Barr virus in preinvasive lesions related to nasopharyngeal carcinoma. , 1995, The New England journal of medicine.

[31]  W. Pao,et al.  Pediatric nasopharyngeal carcinoma: long term follow-up of 29 patients. , 1989, International journal of radiation oncology, biology, physics.

[32]  Pelayo Vilar,et al.  Nasopharyngeal Carcinoma , 1966 .

[33]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[34]  R. Ribeiro,et al.  Prognostic factors and long‐term outcomes of childhood nasopharyngeal carcinoma , 2011, Cancer.

[35]  N. Toumi,et al.  [Pediatric nasopharyngeal carcinoma: Anatomoclinic aspects, therapeutic results and evolutive particularities]. , 2010, Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique.

[36]  M. Adhi,et al.  Pediatric nasopharyngeal carcinoma: A review of 27 cases over 10 years at Shaukat Khanum Memorial Cancer Hospital and Research Center, Pakistan. , 2009, Asian Pacific journal of cancer prevention : APJCP.

[37]  Z. Ülger,et al.  Incidence of hypothyroidism after radiotherapy for nasopharyngeal carcinoma , 2007, Medical oncology.

[38]  P. Pedrazzoli,et al.  Adoptive transfer of allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T cells with in vitro antitumor activity boosts LMP2-specific immune response in a patient with EBV-related nasopharyngeal carcinoma. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[39]  I. Ayan,et al.  Childhood nasopharyngeal carcinoma: from biology to treatment. , 2003, The Lancet. Oncology.

[40]  M Van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.